Bronchodilator response to formoterol Turbuhaler in patients with COPD under regular treatment with formoterol Turbuhaler

Pulmonary Pharmacology and Therapeutics

Volumn 16, Issue 2, 2003, Pages 105-109

  Cazzola, Mario ^a   Matera, Maria Gabriella ^a   D'Amato, Maria ^a   Califano, Clara ^a   Sanduzzi, Alessandro ^b   Vatrella, Alessandro ^b   D'Amato, Gennaro ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

COPD; Formoterol; Turbuhaler

Indexed keywords

BRONCHODILATING AGENT; FORMOTEROL; SALBUTAMOL;

ADULT; AGED; ARTICLE; BRONCHODILATATION; BRONCHODILATING ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAINTENANCE THERAPY; MALE; METERED DOSE INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 0242669267     PISSN: 10945539     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1094-5539(02)00182-7     Document Type: Article

References (22)

1. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease: inpatient management of COPD. Am J Respir Crit Care Med. 152:1995;S72-S120.
2. 2-adrenoceptor expression in human lung. Eur J Pharmacol. 318:1996;123-129.
3. Jaeschke R., Guyatt G.H., Cook D., et al. The effect of increasing doses of β-agonists on airflow in patients with chronic airflow limitation. Respir Med. 87:1993;433-438.
4. Fromm R.E. Jr, Varon J. Acute exacerbations of obstructive lung disease. What to do when immediate care is crucial. Postgrad Med. 95:1994;101-106.
5. 2-agonists be considered an alternative first choice option for the treatment of stable COPD? Respir Med. 93:1999;227-229.
6. 2-agonists in the management of stable chronic obstructive pulmonary disease. Drugs. 60:2000;307-320.
7. Tattersfield A.E., Löfdahl C.-G., Postma D.S., et al. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. Lancet. 357:2001;257-361.
8. Cazzola M., Matera M.G., Santangelo G., et al. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med. 89:1995;357-362.
9. Ullman A., Löfdahl C.G., Melander B., et al. Formoterol inhaled as dry powder or via pressurized metered-dose inhaler in a cumulative dose-response study. Allergy. 51:1996;745-748.
10. Cazzola M., Centanni S., Regolda C., et al. Onset of action of single doses of formoterol administered via Turbuhaler in patients with stable COPD. Pulm Pharmacol Ther. 14:2001;41-45.
11. Jeppsson A.B., Nilsson E., Waldeck B. Formoterol and salmeterol are both long acting compared to terbutaline in the isolated perfused and ventilated guinea-pig lung. Eur J Pharmacol. 257:1994;137-143.
12. Ringdal N., Derom E., Wahlin-Boll E., et al. Onset and duration of action of single doses of formoterol inhaled via Turbuhaler. Respir Med. 92:1998;1017-1021.
13. Pauwels R.A., Löfdahl C.-G., Postma D.S., et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med. 337:1997;1405-1411.
14. 2-agonists. Is there cause for concern? Drug Saf. 16:1997;295-308.
15. Lipworth B.J., Grove A. Evaluation of partial β-adrenoceptor agonist activity. Br J Clin Pharmacol. 43:1997;9-14.
16. Standardization of spirometry - 1994 update. Am J Respir Crit Care Med. 152:1995;1107-1136.
17. 2-adrenoceptor agonist: interactions in human-contracted bronchi. Eur Respir J. 11:1998;583-588.
18. Cazzola M., Di Perna F., Noschese P., et al. Effects of a pre-treatment with conventional doses of formoterol, salmeterol or oxitropium bromide on the dose-response curves to salbutamol in patients suffering from partially reversible COPD. Eur Respir J. 10:1998;1337-1341.
19. Taube C., Lehnigk B., Paasch K., et al. Factor analysis of changes in dyspnea and lung function parameters after bronchodilation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 162:2000;216-220.
20. O'Donnell D.E., Lam M., Webb K.A. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in COPD. Am J Respir Crit Care Med. 160:1999;542-549.
21. Borgstrom L., Derom E., Stahl E., et al. The inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am J Respir Crit Care Med. 153:1996;1636-1640.
22. Löfdahl C.G., Andesson L., Bondesson E., et al. Differences in bronchodilating potency of salbutamol in Turbuhaler as compared with a pressurised metered-dose inhaler formulation in patients with reversible airway obstruction. Eur Respir J. 10:1997;2474-2478.